EMEA-002010-PIP01-16-M01

Key facts

Active substance
axicabtagene ciloleucel
Therapeutic area
Oncology
Decision number
P/0004/2019
PIP number
EMEA-002010-PIP01-16-M01
Pharmaceutical form(s)
Dispersion for infusion
Condition(s) / indication(s)
Treatment of mature B-cell neoplasms
Route(s) of administration
Intravenous use
Contact for public enquiries
Kite Pharma EU B.V.

Tel. +1 4242091332
E-mail: regulatory@kitepharma.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating